The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients-Reference-Cited by-同舟云学术

The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients

Published:2023-04 Issue:3 Volume:14 Page:101474
ISSN:1879-4068
Container-title:Journal of Geriatric Oncology
language:en
Short-container-title:Journal of Geriatric Oncology

Author:

Dotan Efrat,Catalano Paul,Lenchik Leon,Boutin Robert,Yao Xin,Marques Helga S.,Ioffe Dina,Zhen David B.,Li Daneng,Wagner Lynne I.,Simon Melissa A.,Wong Terence Z.,O'Dwyer Peter J.

Publisher

Elsevier BV

Subject

Geriatrics and Gerontology,Oncology

Reference71 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020

3. SEER Cancer Statistics Review,1975

4. The Next Four Decades: The Older Population in the United States - 2010 to 2050: Population Estimates and Projections;Vincent;U.S. Census Bureau,2010

5. American Community Survey 5-Year Estimates;Bureau. USC,2012

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Geriatric assessment for the practicing clinician: The why, what, and how;CA: A Cancer Journal for Clinicians;2024-08-29

2. Fibroblasts in the Aged Pancreas Drive Pancreatic Cancer Progression;Cancer Research;2024-02-08

3. Assessing Frailty in Gastrointestinal Cancer: Two Diseases in One?;Current Oncology Reports;2024-01

4. A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01);BMC Cancer;2023-06-16

5. A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01);2023-05-26